本総説は，平成 17 年度日本薬学会九州支部奨励賞の受 賞を記念して記述したものである． 415 YAKUGAKU ZASSHI 126(6) 415-422 (2006) Metastatic breast cancer (MBC) is almost always incurable, and the median survival is of the order on 18-24 months. Combination therapy with adriamycin (ADR) and docetaxel (DOC) is more eŠective against MBC than the previous therapy due to diŠerences between their mechanisms. However, the combination of ADR and DOC induces severe adverse eŠects, limiting its clinical use in many patients with MBC. The biologic functions of most living organisms are organized along an approximate 24 h time cycle or circadian rhythm. Chronotherapy is deˆned as the administration of medications using biological rhythms to optimize the therapeutic outcomes and/or control adverse eŠects. To decrease adverse eŠects, many antitumor drugs have been particularly studied in humans and animals. The toxicities of ADR and DOC have also been found to depend on dosing-time in animals and humans. This study was to establish the most suitable dosing schedule to relieve severe adverse eŠects and improve antitumor eŠects by considering a chronopharmacological approach, dosing-interval and dosing-sequence to the combination chemotherapy of ADR and DOC in mice. In the results, we demonstrate that the dosing schedule based on dosing-sequence, dosing-interval and dosing-time not only signiˆcantly reduced leukopenia and toxic death but also signiˆcantly increased the inhibition rate of tumor growth compared with the dosing schedule without an interval between each injection, commonly used in clinical practice. Theseˆndings suggest that the therapeutic index of combined chemotherapy can be improved by choosing an optimal dosing-schedule (dosing-interval, dosing-sequence and dosing-time).
and Leukocyte Counts (B) after ADR or CPT-11 Injection (A) ADR (5 mg/kg, i.p.) was administered every 7 days （total of 30 mg/kg) at 10：00, 16：00, 22：00, or 4：00 in rats (n＝10, respectively). The survival days were drawn with the Kaplan-Meier method. Mortality was signiˆcantly higher at 16：00 than at 10：00, 22：00 or 4：00 (vs. 10：00 and 22：00：p＜0.05, vs. 4：00: p＜0.01). (B) CPT-11 (100 mg/kg, i.p.) was administered at 5：00 or 17：00 (n＝10-11, respectively). The values shown are means±S.E. The leukocyte counts in the group treated at 5：00 decreased signiˆcantly compared with those at 17：00 on day 3 (p＜0.01). (A) ADR (5 mg/kg, i.p.) and DOC (12.5 mg/kg, i.p.) were administered every 7 days intermittently (DOC(9：00)-ADR(21：00) (n＝10) and DOC(21： 00)-ADR(9：00) (n＝10)) in mice. Each value is the mean±S.D. On day 10, the leukopenia in the DOC(21：00)-ADR(9：00) group was severer than that in the control and D(9：00)-A(21：00) group (p＜0.01 and p＝0.052, ScheŠe's test). (B) The cell cycle G2-M phase distribution in myelocyte cells (1×10 7 cells) was measured at 9：00, 13：00, 17：00, 21：00, 1：00 or 5：00 (n＝7 or 8). The change rate in the cell cycle (G 2-M phase) sets the mean value of all times at 1. Each value is the mean±S.E. of 7 or 8. The G 2 -M phase of the cell cycle in myelocyte cells in non-treated mice showed a signiˆcant 24 h rhythm with a peak at 5：00 and trough at 17：00 (F from ANOVA＝5.51, p＜0.01; p from cosinor＜0.01). ) and DOC (12.5 mg/kg, i.p.) was administered simultaneously at 5：00 or 17：00 in mice (n＝13, respectively). The survival rate in the group treated at 5：00 decreased signiˆcantly compared with that at 17：00 on day 7 (p＜0.01). 
抗腫瘍効果の向上が可能となることが報告されてき た．

その機序解明を薬物動態学的側面より行ったが，
DOC(9：00)-ADR(21：00）群及び DOC(21：00)
-
